Practical vs Recent Clinical Trial Use Of Dalbavancin - Takeaways - MDSpire

Practical vs Recent Clinical Trial Use Of Dalbavancin

  • By

  • Sarah A. Uhm

  • Bryan T. Alexander

  • Elizabeth R. Lyden

  • Nicolas Cortes-Penfield

  • Harlan R. Sayles

  • Sara F. Azimi

  • Mackenzie R. Keintz

  • Molly M. Miller

  • Mark E. Rupp

  • Jasmine R. Marcelin

  • June 3, 2026

  • 0 min

Share

  • 1

    Dalbavancin is approved for gram-positive acute bacterial skin infections and increasingly used off-label for bacteremia.

  • 2

    Patients receiving dalbavancin in clinical practice were younger and had higher rates of substance use compared to DOTS trial participants.

  • 3

    The clinical success rate at day 70 was 65% in the clinical cohort, lower than the 80% seen in the DOTS trial.

  • 4

    Despite a higher percentage of patients with prolonged bacteremia, clinical failure rates remained low in the clinical cohort.

  • 5

    This study's limitations include its retrospective design, small sample size, and potential selection bias affecting outcome assessment.

Original Source(s)

Practical vs Recent Clinical Trial Use Of Dalbavancin

  • by Sarah A. Uhm, Bryan T. Alexander, Elizabeth R. Lyden, Nicolas Cortes-Penfield, Harlan R. Sayles, Sara F. Azimi, Mackenzie R. Keintz, Molly M. Miller, Mark E. Rupp, Jasmine R. Marcelin

  • June 3, 2026

Related Content

Clinical outcomes of tibial cortex transverse transport versus antibiotic-loaded bone cement for Wagner grade 3–4 diabetic foot ulcers: a real-world retrospective cohort study

Hospital AI Fails to Flag Drug Diversion

"I've never myself seen these technologies be called out in that specific way"

Codonopsis pilosula polysaccharide attenuates the inflammatory response in macrophages induced by Brucella abortus outer membrane protein 19 via regulating ATP2A1 to modulate cell adhesion and calcium signaling